Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,854
  • Shares Outstanding, K 6,406
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,120 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.39
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9800 +9.18%
on 11/27/24
1.3000 -17.69%
on 12/04/24
+0.0500 (+4.90%)
since 11/20/24
3-Month
0.9355 +14.38%
on 10/10/24
1.3000 -17.69%
on 12/04/24
+0.0200 (+1.90%)
since 09/20/24
52-Week
0.7650 +39.87%
on 02/23/24
4.1699 -74.34%
on 03/01/24
-0.6601 (-38.15%)
since 12/20/23

Most Recent Stories

More News
Adial Pharmaceuticals Secures Expanded Patent for Genotype-Based Treatment of Alcohol Use Disorder

Adial Pharmaceuticals receives a patent for expanded genotype coverage in treating alcohol use disorder with its drug AD04.Quiver AI SummaryAdial Pharmaceuticals, a clinical-stage biopharmaceutical company...

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Announces Topline Results For Onwardâ„¢ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an...

ADIL : 1.0700 (+1.90%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals to Announce Topline Results of ONWARDâ„¢ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder

Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET...

ADIL : 1.0700 (+1.90%)
ADILW : 0.0009 (-57.14%)

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

3rd Resistance Point 1.1633
2nd Resistance Point 1.1167
1st Resistance Point 1.0933
Last Price 1.0700
1st Support Level 1.0233
2nd Support Level 0.9767
3rd Support Level 0.9533

See More

52-Week High 4.1699
Fibonacci 61.8% 2.8692
Fibonacci 50% 2.4674
Fibonacci 38.2% 2.0657
Last Price 1.0700
52-Week Low 0.7650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar